CA3033846C - CHIMERIC ANTIGEN RECEPTOR WITH DOMAIN I SPECIFIC TO INTERCELLULAR ADHESION MOLECULE 1 - Google Patents

CHIMERIC ANTIGEN RECEPTOR WITH DOMAIN I SPECIFIC TO INTERCELLULAR ADHESION MOLECULE 1

Info

Publication number
CA3033846C
CA3033846C CA3033846A CA3033846A CA3033846C CA 3033846 C CA3033846 C CA 3033846C CA 3033846 A CA3033846 A CA 3033846A CA 3033846 A CA3033846 A CA 3033846A CA 3033846 C CA3033846 C CA 3033846C
Authority
CA
Canada
Prior art keywords
icam
human
cells
domain
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3033846A
Other languages
English (en)
French (fr)
Other versions
CA3033846A1 (en
Inventor
Moonsoo Jin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of CA3033846A1 publication Critical patent/CA3033846A1/en
Application granted granted Critical
Publication of CA3033846C publication Critical patent/CA3033846C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
CA3033846A 2016-09-02 2017-08-11 CHIMERIC ANTIGEN RECEPTOR WITH DOMAIN I SPECIFIC TO INTERCELLULAR ADHESION MOLECULE 1 Active CA3033846C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662383139P 2016-09-02 2016-09-02
US62/383,139 2016-09-02
US201662419817P 2016-11-09 2016-11-09
US62/419,817 2016-11-09
PCT/US2017/046630 WO2018052594A1 (en) 2016-09-02 2017-08-11 I domain chimeric antigen receptor specific to icam-1

Publications (2)

Publication Number Publication Date
CA3033846A1 CA3033846A1 (en) 2018-03-22
CA3033846C true CA3033846C (en) 2025-03-11

Family

ID=61281980

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3033846A Active CA3033846C (en) 2016-09-02 2017-08-11 CHIMERIC ANTIGEN RECEPTOR WITH DOMAIN I SPECIFIC TO INTERCELLULAR ADHESION MOLECULE 1

Country Status (10)

Country Link
US (6) US10577408B2 (OSRAM)
EP (1) EP3522718B1 (OSRAM)
JP (1) JP6996772B2 (OSRAM)
KR (1) KR102613109B1 (OSRAM)
CN (1) CN108697096B (OSRAM)
AU (1) AU2017325678B2 (OSRAM)
CA (1) CA3033846C (OSRAM)
ES (1) ES2971550T3 (OSRAM)
SG (1) SG11201901505SA (OSRAM)
WO (2) WO2018052594A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10577408B2 (en) * 2016-09-02 2020-03-03 Cornell University Transduced T cells expressing human SSTR2 and application thereof
US11517627B2 (en) 2017-01-20 2022-12-06 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
EP3607319A1 (en) * 2017-04-07 2020-02-12 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
US11866494B2 (en) * 2018-08-31 2024-01-09 Innovative Cellular Therapeutics Holdings, Ltd. CAR T therapy through uses of co-stimulation
EP4259285A4 (en) * 2020-12-09 2024-12-11 Affyimmune Therapeutics, Inc. DUAL CHIMERIC ANTIGEN RECEPTOR TARGETING EPCAM AND ICAM-1
CN114907485B (zh) * 2021-02-08 2024-04-26 浙江大学 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体
JP2025531030A (ja) * 2022-09-14 2025-09-19 バイオセプター （オースト） プロプライエタリー・リミテッド 免疫細胞のインビボ検出
US12385818B2 (en) 2023-02-14 2025-08-12 Saudi Arabian Oil Company Modeling gas desorption in a subsurface reservoir
WO2024206155A1 (en) 2023-03-24 2024-10-03 Cornell University Utilizing t cells derived from tumor draining lymph nodes for chimeric antigen receptor (car) t cell therapy for the treatment of cancer
WO2025188678A1 (en) * 2024-03-04 2025-09-12 AffyImmune Therapeutics Inc. Icam-1 targeted car constructs and methods of treatment

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013584A1 (en) 1994-11-01 1996-05-09 Targeted Genetics Corporation Chimeric receptors for the generation of selectively-activatable th-independent cytotoxic t cells
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP2002541845A (ja) 1999-04-16 2002-12-10 セルテック セラピューティックス リミテッド 合成膜貫通成分
IL152316A0 (en) 2000-06-09 2003-05-29 Bristol Myers Squibb Co Pharmaceutical compositions and kits for treating transplant rejection
US7176187B2 (en) 2001-02-15 2007-02-13 Board Of Regents, The University Of Texas System Fusion proteins based upon somatostatin receptors
WO2007070488A2 (en) * 2005-12-12 2007-06-21 The Cbr Institute For Biomedical Research, Inc. Integrin alpha l i domain mutants with increased binding affinity
US9731023B2 (en) 2010-09-08 2017-08-15 Board Of Regents, The University Of Texas System Somatostatin receptor-based cancer therapy
EP2765193B1 (en) * 2011-10-07 2017-08-09 Mie University Chimeric antigen receptor
US10144770B2 (en) * 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
EP3287135A4 (en) * 2015-03-20 2019-03-27 Mie University THERAPEUTICS RELATED TO THE SUPPRESSION OF PROLIFERATION AND METASTASIC FORMATION OF CANCER WITH CYTOTOXIC T CELLS RELEASED EXOSOMES AND FACED AGAINST ELECTRICITY / MESENCHYMAL CANCER CELLS
US10577408B2 (en) * 2016-09-02 2020-03-03 Cornell University Transduced T cells expressing human SSTR2 and application thereof

Also Published As

Publication number Publication date
EP3522718A1 (en) 2019-08-14
EP3522718A4 (en) 2020-02-19
US20180066035A1 (en) 2018-03-08
US12325736B2 (en) 2025-06-10
US10577408B2 (en) 2020-03-03
CA3033846A1 (en) 2018-03-22
AU2017325678A1 (en) 2019-03-14
KR102613109B1 (ko) 2023-12-13
ES2971550T3 (es) 2024-06-05
US10428136B2 (en) 2019-10-01
WO2018044534A1 (en) 2018-03-08
KR20190057072A (ko) 2019-05-27
WO2018052594A1 (en) 2018-03-22
JP6996772B2 (ja) 2022-02-21
US12410235B2 (en) 2025-09-09
US20210309721A1 (en) 2021-10-07
US11634471B2 (en) 2023-04-25
JP2019530441A (ja) 2019-10-24
US20180066037A1 (en) 2018-03-08
US20230265165A1 (en) 2023-08-24
AU2017325678B2 (en) 2022-03-17
US20200017573A1 (en) 2020-01-16
EP3522718B1 (en) 2023-07-05
CN108697096A (zh) 2018-10-23
SG11201901505SA (en) 2019-03-28
US11046748B2 (en) 2021-06-29
US20200181238A1 (en) 2020-06-11
CN108697096B (zh) 2022-05-03

Similar Documents

Publication Publication Date Title
CA3033846C (en) CHIMERIC ANTIGEN RECEPTOR WITH DOMAIN I SPECIFIC TO INTERCELLULAR ADHESION MOLECULE 1
ZA202203511B (en) Disrupting tumor tissues by targeting fibroblast activation protein (fap)
JOP20200237A1 (ar) الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
EA202091566A1 (ru) Содержащая нуклеиновую кислоту липидная наночастица и ее применение
IN2015KN00350A (OSRAM)
EA201590207A1 (ru) Композиции и способы регуляции car-т-клеток
EA201170158A1 (ru) Агенты, связывающиеся с рецептором notch1, и способы их применения
MX2014000555A (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
CR20190440A (es) Receptores de unión a antígeno mejorados
BR112017027498A2 (pt) anticorpo, ácido nucleico, composto, composição, e, método para tratamento de um paciente com uma doença.
SG10201805411YA (en) Chimeric antigen receptors
BR112012004546A8 (pt) Terapêutica por proteínas ligantes dll4-ligantes
NZ737726A (en) Multispecific antigen-binding molecules and uses thereof
BR112014029099A2 (pt) anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende
MY204740A (en) Antagonistic cd40 monoclonal antibodies and uses thereof
WO2019204462A3 (en) Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
PH12022551032A1 (en) Bcma-targeted car-t cell therapy of multiple myeloma
BR112014016652A2 (pt) construtos de mhc parciais e médodos de uso
CN104245736A (zh) 抗人死亡受体5胞外区的人源化单克隆抗体
MX2021012335A (es) Anticuerpos humanos que se unen a ret y metodos de uso de los mismos.
MX2021002208A (es) Regimenes de dosificacion de la proteina de fusion de fc y dominio extracelular del cd80.
MY203356A (en) Antisense oligonucleotides targeting alpha-synuclein and uses thereof
WO2021211510A3 (en) Epcam antibody and car-t cells
Krause et al. Simultaneous PLK1 inhibition improves local tumour control after fractionated irradiation
AR110620A1 (es) Terapias combinadas de receptores de antígeno quiméricos e inhibidores de pd-1

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802